219 related articles for article (PubMed ID: 21493743)
1. Long-term results of a randomized controlled trial in childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Saito M; Sako M; Ishikura K; Hataya H; Honda M; Iijima K; Yoshikawa N;
Clin J Am Soc Nephrol; 2011 Jun; 6(6):1301-7. PubMed ID: 21493743
[TBL] [Abstract][Full Text] [Related]
2. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy.
Shima Y; Nakanishi K; Kamei K; Togawa H; Nozu K; Tanaka R; Sasaki S; Iijima K; Yoshikawa N
Nephrol Dial Transplant; 2011 Jan; 26(1):163-9. PubMed ID: 20601366
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.
Yoshikawa N; Ito H; Sakai T; Takekoshi Y; Honda M; Awazu M; Ito K; Iitaka K; Koitabashi Y; Yamaoka K; Nakagawa K; Nakamura H; Matsuyama S; Seino Y; Takeda N; Hattori S; Ninomiya M
J Am Soc Nephrol; 1999 Jan; 10(1):101-9. PubMed ID: 9890315
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.
Shima Y; Nakanishi K; Kaku Y; Ishikura K; Hataya H; Matsuyama T; Honda M; Sako M; Nozu K; Tanaka R; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2018 Nov; 33(11):2103-2112. PubMed ID: 29987456
[TBL] [Abstract][Full Text] [Related]
5. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N; Honda M; Iijima K; Awazu M; Hattori S; Nakanishi K; Ito H;
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy--is it relevant for adult patients?
Yoshikawa N; Ito H
Nephrol Dial Transplant; 1999 May; 14(5):1097-9. PubMed ID: 10344344
[No Abstract] [Full Text] [Related]
7. Combination therapy with mizoribine for severe childhood IgA nephropathy: a pilot study.
Yoshikawa N; Nakanishi K; Ishikura K; Hataya H; Iijima K; Honda M;
Pediatr Nephrol; 2008 May; 23(5):757-63. PubMed ID: 18224343
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy.
Kamei K; Nakanishi K; Ito S; Ishikura K; Hataya H; Honda M; Nozu K; Iijima K; Shima Y; Yoshikawa N;
Pediatr Nephrol; 2015 Jun; 30(6):961-7. PubMed ID: 25487669
[TBL] [Abstract][Full Text] [Related]
9. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
Pozzi C; Andrulli S; Pani A; Scaini P; Roccatello D; Fogazzi G; Pecchini P; Rustichelli R; Finocchiaro P; Del Vecchio L; Locatelli F
J Nephrol; 2013; 26(1):86-93. PubMed ID: 22460183
[TBL] [Abstract][Full Text] [Related]
10. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
Li X; Liu Y; Lv J; Shi S; Liu L; Chen Y; Zhang H
Clin J Am Soc Nephrol; 2014 Mar; 9(3):484-9. PubMed ID: 24408121
[TBL] [Abstract][Full Text] [Related]
11. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy.
Ballardie FW; Roberts ISD
J Am Soc Nephrol; 2002 Jan; 13(1):142-148. PubMed ID: 11752031
[TBL] [Abstract][Full Text] [Related]
12. Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study).
Shima Y; Nakanishi K; Sako M; Saito-Oba M; Hamasaki Y; Hataya H; Honda M; Kamei K; Ishikura K; Ito S; Kaito H; Tanaka R; Nozu K; Nakamura H; Ohashi Y; Iijima K; Yoshikawa N;
Pediatr Nephrol; 2019 May; 34(5):837-846. PubMed ID: 30284023
[TBL] [Abstract][Full Text] [Related]
13. Comparison of antiproteinuric effects of two different combination therapies in children with IgA nephropathy.
Yagi K; Okada M; Yanagida H; Kuwajima H; Ikeda M; Sugimoto K; Takemura T
Clin Exp Nephrol; 2003 Dec; 7(4):270-4. PubMed ID: 14712355
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy.
Kawasaki Y; Suzuki J; Sakai N; Etoh S; Murai H; Nozawa R; Suzuki H
Am J Nephrol; 2004; 24(1):147-53. PubMed ID: 14726626
[TBL] [Abstract][Full Text] [Related]
15. Crescentic IgA nephropathy in children.
Shima Y; Nakanishi K; Hama T; Mukaiyama H; Sato M; Tanaka Y; Tanaka R; Kaito H; Nozu K; Sako M; Iijima K; Yoshikawa N
Pediatr Nephrol; 2020 Jun; 35(6):1005-1014. PubMed ID: 31993782
[TBL] [Abstract][Full Text] [Related]
16. IgA nephropathy with presentation of nephrotic syndrome at onset in children.
Shima Y; Nakanishi K; Sato M; Hama T; Mukaiyama H; Togawa H; Tanaka R; Nozu K; Sako M; Iijima K; Suzuki H; Yoshikawa N
Pediatr Nephrol; 2017 Mar; 32(3):457-465. PubMed ID: 27714465
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressive agents for treating IgA nephropathy.
Vecchio M; Bonerba B; Palmer SC; Craig JC; Ruospo M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2015 Aug; (8):CD003965. PubMed ID: 26235292
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
19. Improved renal survival in Japanese children with IgA nephropathy.
Yata N; Nakanishi K; Shima Y; Togawa H; Obana M; Sako M; Nozu K; Tanaka R; Iijima K; Yoshikawa N
Pediatr Nephrol; 2008 Jun; 23(6):905-12. PubMed ID: 18224344
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of immunosuppressive therapy in IgA nephropathy presenting with isolated hematuria.
Harmankaya O; Oztürk Y; Baştürk T; Obek A; Kiliçarslan I
Int Urol Nephrol; 2002; 33(1):167-71. PubMed ID: 12090325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
